Prevention of Early Sudden Cardiac Death after Myocardial Infarction Using the Wearable Cardioverter Defibrillator-Results from a Real-World Cohort.
Ursula RohrerMartin ManningerLukas FiedlerClemens SteinwenderRonald K BinderMarkus StühlingerBirgit ZirngastDavid ZweikerAndreas ZirlikDaniel Scherrnull nullPublished in: Journal of clinical medicine (2023)
The WCD is a safe treatment option in a highly selected cohort of patients with LVEF ≤ 35% after AMI. However, despite excellent WCD wearing duration in our cohort, the arrhythmic mortality rate was not significantly different.